



11 β -Hydroxysteroid dehydrogenases control access of 7 β ,27-dihydroxycholesterol to retinoid-related orphan receptor γ ^S

Katharina R. Beck,* Silvia G. Inderbinen,* Sharavan Kanagaratnam,* Denise V. Kratschmar,* Anton M. Jetten,[†] Hideaki Yamaguchi,[§] and Alex Odermatt^{1,*}

Division of Molecular and Systems Toxicology,* Department of Pharmaceutical Sciences, University of Basel, 4056 Basel, Switzerland; Immunity, Inflammation, and Disease Laboratory,[†] National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709; and Department of Applied Biological Chemistry,[§] Meijo University, Nagoya 468-8502, Japan

ORCID ID: 0000-0002-6820-2712 (A.O.)

Abstract Oxysterols previously were considered intermediates of bile acid and steroid hormone biosynthetic pathways. However, recent research has emphasized the roles of oxysterols in essential physiologic processes and in various diseases. Despite these discoveries, the metabolic pathways leading to the different oxysterols are still largely unknown and the biosynthetic origin of several oxysterols remains unidentified. Earlier studies demonstrated that the glucocorticoid metabolizing enzymes, 11 β -hydroxysteroid dehydrogenase (11 β -HSD) types 1 and 2, interconvert 7-ketocholesterol (7kC) and 7 β -hydroxycholesterol (7 β OHC). We examined the role of 11 β -HSDs in the enzymatic control of the intracellular availability of 7 β ,27-dihydroxycholesterol (7 β 27OHC), a retinoid-related orphan receptor γ (ROR γ) ligand. We used microsomal preparations of cells expressing recombinant 11 β -HSD1 and 11 β -HSD2 to assess whether 7 β 27OHC and 7-keto,27-hydroxycholesterol (7k27OHC) are substrates of these enzymes. Binding of 7 β 27OHC and 7k27OHC to 11 β -HSDs was studied by molecular modeling. To our knowledge, the stereospecific oxoreduction of 7k27OHC to 7 β 27OHC by human 11 β -HSD1 and the reverse oxidation reaction of 7 β 27OHC to 7k27OHC by human 11 β -HSD2 were demonstrated for the first time. Apparent enzyme affinities of 11 β -HSDs for these novel substrates were equal to or higher than those of the glucocorticoids. This is supported by the fact that 7k27OHC and 7 β 27OHC are potent inhibitors of the 11 β -HSD1-dependent oxoreduction of cortisone and the 11 β -HSD2-dependent oxidation of cortisol, respectively. Furthermore, molecular docking calculations explained stereospecific enzyme activities.

Finally, using an inducible ROR γ reporter system, we showed that 11 β -HSD1 and 11 β -HSD2 controlled ROR γ activity.[■] These findings revealed a novel glucocorticoid-independent prereceptor regulation mechanism by 11 β -HSDs that warrants further investigation.—Beck, K. R., S. G. Inderbinen, S. Kanagaratnam, D. V. Kratschmar, A. M. Jetten, H. Yamaguchi, and A. Odermatt. 11 β -Hydroxysteroid dehydrogenases control access of 7 β ,27-dihydroxycholesterol to retinoid-related orphan receptor γ . *J. Lipid Res.* 2019. 60: 1535–1546.

Supplementary key words oxysterol • 27-hydroxylase • mineralocorticoid receptor • retinoid-related orphan receptor gamma

Oxysterols originate from cholesterol or cholesterol precursors and previously were mainly considered intermediates of bile acid and steroid hormone biosynthetic pathways. They display additional oxygen functionalities in the ring system and/or at the side chain of cholesterol, deriving through either enzymatic reactions and/or radical processes (1). Oxysterols are involved in several physiological processes including cholesterol, carbohydrate, and lipid homeostasis, immune system regulation, and neuronal

Abbreviations: BHT, butylated hydroxytoluene; CHO, Chinese hamster ovary; CYP27A1, 27-hydroxylase; 11-DHC, 11-dehydrocorticosterone; GA, glycyrrhetic acid; GALF, glycyrrhetic acid-like factor; H6PDH, hexose-6-phosphate dehydrogenase; 11 β -HSD, 11 β -hydroxysteroid dehydrogenase; IBD, inflammatory bowel disease; ILC3, innate lymphoid cells group 3; 7kC, 7-ketocholesterol; 7k27OHC, 7-keto, 27-hydroxycholesterol; 27OHC, 27-hydroxycholesterol; 7 β OHC, 7 β -hydroxycholesterol; 7 β 27OHC, 7 β ,27-hydroxycholesterol; MR, mineralocorticoid receptor; ROR γ , retinoid-related orphan receptor γ ; Smo, Smoothened; T0504, 5H-1,2,4-triazolo(4,3-a)azepine,6,7,8,9-tetrahydro-3-tricyclo(3-3-1-13-7)dec-1-yl (also known as Merck-544); TPP, triphenylphosphine.

¹To whom correspondence should be addressed.

e-mail: Alex.Odermatt@unibas.ch;

[■] The online version of this article (available at <http://www.jlr.org>) contains a supplement.

This work was supported by Swiss National Science Foundation Grant 31003A-179400 (A.O.) and the Intramural Research Program of the National Institute of Environmental Health Sciences, Foundation for the National Institutes of Health Grant Z01-ES-101585 (A.M.J.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors declare no conflicts of interest.

*Author's Choice—Final version open access under the terms of the Creative Commons CC-BY license.

Manuscript received 30 January 2019 and in revised form 24 June 2019.

Published, JLR Papers in Press, July 4, 2019

DOI <https://doi.org/10.1194/jlr.M092908>

Copyright © 2019 Beck et al. Published by The American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at <http://www.jlr.org>

development. Furthermore, recent research emphasized their role as bioactive lipids, contributing to the progression of various pathologies, such as neurodegenerative diseases, atherosclerosis, and cancer [reviewed in (2–6)]. Nevertheless, the metabolic pathways leading to the different oxysterols remain insufficiently understood and their biosynthetic origins need to be elucidated.

7-Ketocholesterol (7kC) is one of the most extensively studied oxysterols and particularly known for its pro-inflammatory and cytotoxic properties [reviewed in (1, 7, 8)], and it was recently reported to be associated with cardiovascular outcomes and total mortality in patients with coronary artery disease (9). However, it remains unclear whether 7kC itself or its metabolites caused these biological effects. In situ, 7kC is mainly generated by autoxidation of cholesterol during conditions of oxidative stress. In contrast to the low abundance of oxysterols in the circulation compared with cholesterol, 7kC is present at levels up to 10 μ M in macrophage-derived foam cells in atherosclerotic lesions and in lenses of patients with cataract (10–12). In macrophages and in the retinal pigment epithelium, sterol 27-hydroxylase (CYP27A1) was found to convert 7kC to 7-keto,27-hydroxycholesterol (7k27OHC) by (13, 14). This metabolic step is ablated in macrophages derived from patients suffering from cerebrotendinous xanthomatosis, bearing a defect in the gene encoding CYP27A1 (13). These patients have normal circulating cholesterol, but increased 7kC levels, and are prone to the development of premature atherosclerosis (15).

Hepatic conversion of dietary 7kC to 7k27OHC is evident because the mitochondrial CYP27A1 is the first enzyme involved in the alternative biosynthesis pathway of bile acids in the liver (16, 17). However, a study with mice bearing a homozygous null mutation in the *Cyp27* gene showed rapid and extensive hepatic 7kC metabolism, indicating the involvement of another enzyme (18). This enzyme was later proposed to be 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1), stereo-specifically converting 7kC into 7 β -hydroxycholesterol (7 β OHC) in humans, rats, and mice (19–21). Data from transgenic 11 β -hsd1-deficient mice exhibiting an increased 7kC to 7 β OHC ratio in liver tissue samples further supported these results (22).

The role of 11 β -HSD1, well-known for the local conversion of glucocorticoids from inactive to active, in oxysterol metabolism and atherosclerotic plaque progression has been addressed by several studies [reviewed in (23)]. Interestingly, no direct accumulation of 7kC could be detected in the arterial wall of *hsd11b1*^{-/-} mice (24), and a loss of 11 β -HSD1 function was rather associated with an atheroprotective and beneficial metabolic profile (25–27). Whether the observed favorable effects of diminished 11 β -HSD1 activity are due to decreased intracellular levels of active glucocorticoids, or whether they are glucocorticoid-independent, remained unclear. This raised the hypothesis that 7kC acts as a precursor molecule requiring further downstream processing by another enzyme to exert its activity. Despite the extensive research focusing on the effects of 7kC and 7 β OHC, only a weak interaction of 7kC with the arylhydrocarbon receptor and no cognate high-affinity

receptors have been identified for 7kC and 7 β OHC so far (28). However, for the sidechain-oxidized or the dihydroxylated oxysterols, such as 7 β ,27-dihydroxycholesterol (7 β 27OHC), several targets have been described [reviewed in (2)]. A recent study on Smoothed (Smo)-activating oxysterols suggested the conversion of 7 β OHC to 7kC by 11 β -HSD2, which required further metabolism by CYP27A1 to 7k27OHC in order to regulate Smo activity (29, 30). The enzymatic control of Smo by 11 β -HSDs remains unclear, as both 7k27OHC and 7 β 27OHC were reported to promote Smo activity. Importantly, another receptor, retinoid-related orphan receptor γ (ROR γ), was recently found to be activated by 7 β 27OHC, whereas 7k27OHC did not stimulate full-length ROR γ activity in reporter gene assays (31). Nevertheless, a potential role for 11 β -HSDs in the cell-specific metabolic availability of 7 β 27OHC and 7k27OHC, as they exert for glucocorticoids, has not yet been addressed. Thus, we investigated to determine whether 11 β -HSDs are involved in the metabolism of 7-oxygenated 27OHCs and thereby could control the regulation of target receptors such as ROR γ .

MATERIALS AND METHODS

Chemicals and reagents

7k27OHC, 7 β 27OHC, 7 α 27OHC, and 7 β 27OHC-d6 were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL), [1,2-³H] cortisone, [1,2,6,7-³H]cortisol, and [1,2,6,7-³H] corticosterone from American Radiolabeled Chemicals (St. Louis, MO), and all other chemicals from Sigma-Aldrich (Buchs, Switzerland) of the highest grade available. Cell culture media were purchased from Sigma-Aldrich and Invitrogen (Carlsbad, CA) and FBS approved for use with the Tet-on system from Clontech (Mountain View, CA). UHPLC-grade purity methanol, acetonitrile, and formic acid were from Biosolve (Dieuze, France). 5H-1,2,4-triazolo(4,3-a)azepine,6,7,8,9-tetrahydro-3-tricyclo(3-3-1-1-3-7)dec-1-yl [T0504; also known as Merck-544 (25)] was purchased from Enamine (Kiev, Ukraine).

Cell culture

HEK-293 cells and human SW-620 colon carcinoma cells were obtained from ATCC (Manassas, VA) and cultured in DMEM supplemented with 10% FBS, 4.5 g/l glucose, 100 U/ml penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES (pH 7.4), and 10% MEM nonessential amino acid solution. Doxycycline-inducible ROR γ stable Chinese hamster ovary (CHO) Tet-on cells were cultured in F12 medium containing 10% FBS approved for use with the Tet-on system and 100 U/ml penicillin/streptomycin (32, 33). Cells were regularly tested for the absence of mycoplasma.

11 β -HSD-dependent metabolism of 7-oxygenated 27OHCs in intact cells

Fifty thousand stably transfected HEK-293 cells expressing either 11 β -HSD2 [clone AT8 (34)] or 11 β -HSD1 and hexose-6-phosphate dehydrogenase (H6PDH) [clone HHH7 (35)] were seeded in poly-L-lysine-coated 96-well plates and incubated for 24 h. H6PDH provides the cofactor NADPH and is required for an efficient oxoreduction reaction by 11 β -HSD1 (36). The medium was changed to steroid- and phenol red-free DMEM (DMEM SF) for another 2 h and the cells were then treated with 1 μ M of 7k27OHC in the presence or absence of 1 μ M of T0504 (to inhibit 11 β -HSD1) or 0.5 μ M of 7 β 27OHC or 7 α 27OHC in the presence

or absence of 5 μM of glycyrrhetic acid (GA) (to inhibit 11 β -HSD2). Metabolic conversion was determined after 0.5 h for 11 β -HSD2 and after 1 h for 11 β -HSD1.

SW-620 cells (500,000 cells/well) were seeded in 24-well plates and incubated for 24 h. The culture medium was replaced by DMEM SF containing 1 μM of 7 β OHC in the presence or absence of 10 μM of GA for 3.5 h or 7 h.

Ice-cold acetonitrile/isopropanol (7:3, v/v) mixture containing either 100 nM deuterium-labeled 7 β 27OHC or corticosterone as internal standards were used to extract oxysterols from cell culture supernatants. Additionally, 1.5% (v/v) of a standard solution of the antioxidant butylated hydroxytoluene (BHT) and the peroxide reducing agent triphenylphosphine (TPP) (10 mg BHT and 25 mg TPP in 10 ml ethanol) was added (37). In experiments with SW-620 cells, oxysterols were extracted from cell supernatants and cells. The samples were incubated for 30 min at 4°C and 700 rotations per minute, centrifuged (16,000 g, 10 min, 4°C), and the supernatant evaporated to dryness under nitrogen to minimize oxidation from atmospheric oxygen. After reconstitution in 50 μl of methanol:ultra-pure water (1:1, v/v), the samples were again centrifuged (16,000 g, 10 min, 4°C) and the supernatants analyzed. Data (mean \pm SD) were obtained from three independent experiments.

11 β -HSD enzyme kinetic measurements

Preparation of microsomes. Microsomes were prepared as described earlier with minor modifications (38). Briefly, HEK-293 cells stably expressing human 11 β -HSD1 and H6PDH were cultured until they reached confluence. Then, they were washed with ice-cold PBS and resuspended to a final concentration of $\sim 2 \times 10^7$ cells/ml in ice-cold buffer A [50 mM Tris (pH 7.5), 1 mM EDTA, 100 mM NaCl]. Typically, 6 ml of this suspension were prepared, corresponding to 1.2×10^8 cells. Following homogenization with 20 strokes in a glass potter on ice, the preparation was sonicated and centrifuged (9,000 g, 4°C for 30 min). The supernatant was removed and subjected to ultracentrifugation at 105,000 g, 4°C for 70 min. The obtained pellet was resuspended in buffer B [20 mM Tris (pH 7.5), 1 mM EDTA, 10% glycerol] and the ultracentrifugation step repeated. The microsomal fraction was again resuspended in buffer B and the total protein concentration determined using BCA assay (39). The microsomes were immediately frozen on dry ice and stored at -80°C .

Determination of apparent K_M and V_{max} values. Microsomes (1–20 μg) expressing 11 β -HSD1 and H6PDH were incubated for 20 min with 1 mM of NADPH, 2 mM of glucose-6-phosphate, 0.1 units of glucose-6-phosphate dehydrogenase (from *Saccharomyces cerevisiae*), and different concentrations (62.5–2,000 nM) of 7k27OHC, adapted to a total assay volume of 50 μl with TS2 buffer [100 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM MgCl_2 , 250 mM sucrose, 20 mM Tris/HCl (pH 7.4)]. Oxysterols were extracted by mixing the samples with ice-cold ethyl acetate containing 100 nM deuterium-labeled 7 β 27OHC as internal standard and 1.5% (v/v) BHT/TPP solution as antioxidant. The samples were then incubated for 15 min at 4°C on a rotating mixer, shortly centrifuged, and the upper ethyl acetate phase transferred into a new tube. The extraction step was repeated and the ethyl acetate phases combined and evaporated to dryness under nitrogen. After reconstitution in 50 μl of methanol:ultra-pure water (1:1, v/v), the samples were centrifuged (4°C, 16,000 g for 10 min) and analyzed by UHPLC-MS/MS.

For 11 β -HSD2 activity measurements, 0.8 μg of HEK-293 cell lysate stably expressing 11 β -HSD2 was incubated with different concentrations (50–800 nM) of 7 β 27OHC and 500 μM of NAD^+ for 10–30 min. Oxysterols were extracted as described in the 11 β -HSD-dependent metabolism of 7-oxygenated 27OHCs in intact cells section.

The substrate conversion was kept below 30% in all reactions. Apparent kinetic parameters (K_M and V_{max}) were determined by nonlinear regression and under the assumption of Michaelis-Menten kinetics. Data (mean \pm SD) were obtained from three independent experiments.

Sterol measurement by UHPLC-MS/MS

An Agilent 1290 Infinity UHPLC binary solvent delivery system including a temperature controlled autosampler and a column oven coupled to an Agilent 6490 triple quadrupole mass spectrometer with a jet stream electrospray ionization interface (AJS-ESI) (Agilent Technologies) was used to analyze oxysterols. A reversed-phase column (ACQUITY UPLC BEH C18, 1.7 μm , 2.1×150 mm; Waters, Wexford, Ireland) heated to $65 \pm 0.8^\circ\text{C}$ was applied for analyte separation. The flow-rate was 0.5 ml with solvent A [water/acetonitrile/formic acid (95/5/0.1, v/v/v)] and solvent B [water/acetonitrile/formic acid (5/95/0.1, v/v/v)]. The eluent gradient was set as follows: 0–4.5 min 45–97% B, 4.5–7 min 80% B (washout), and 7–9 min 45% B (column re-equilibration). Methanol/water (75/25, v/v) was used as needle and needle-seat flushing solvent for 10 s after sample aspiration. The samples were stored in the autosampler at 4°C until analysis.

Analyte fragmentation was directed in the positive ion mode for multiple reaction monitoring and source conditions defined by use of the integrated compound- and source-optimizer software module (Agilent Technologies; B.07.01). Multiple reaction monitoring transitions were defined as follows: 7k27OHC (m/z 417.3 \rightarrow 417.3; retention time = 3.59 min), 7 β 27OHC (m/z 383.3 \rightarrow 159.0; retention time = 3.45 min), 7 α 27OHC (m/z 383.3 \rightarrow 383.3 and m/z 159.0; retention time = 3.57 min), 7 β 27OHC-d6 (m/z 407.38 \rightarrow 159.1 and m/z 389.1; retention time = 3.42 min). Separation and retention time of 7k27OHC, 7 α 27OHC, and 7 β 27OHC are shown in supplemental Fig. S1. Source parameters were as follows: gas temperature 290°C, gas flow 14 l/min, sheath gas temperature 300°C, sheath gas flow 11 l/min, nozzle voltage 1,500 V, capillary voltage 3,000 V, cell accelerator voltage 4 V, fragmentation voltage 380 V, and nebulizer 20 psi.

For data acquisition and analysis, MassHunter Workstation Acquisition Software Version 07.01 SP1 and MassHunter Workstation Software Quantitative Analysis Version B.07.00/Build 7.0457.0, respectively (Agilent Technologies), were used.

Inhibition of 11 β -HSD-dependent glucocorticoid metabolism in cell lysates

11 β -HSD1 and 11 β -HSD2 enzyme activities were assessed in lysates of HEK-293 cells stably expressing the respective enzyme as reported earlier (40). Briefly, 11 β -HSD1-dependent oxoreductase activity was determined by the incubation of lysates with 200 nM of radiolabeled cortisone, 500 μM of NADPH, and the test substance or vehicle for 10 min at 37°C. 11 β -HSD2-dependent oxidation of cortisol was measured instead by the addition of 50 nM of radiolabeled cortisol and 500 μM of NAD^+ . The enzymatic reaction was stopped by introducing an excess amount of unlabeled cortisone and cortisol (1:1, 2 mM unlabeled each, in methanol). Cortisone and cortisol were separated using TLC and a chloroform and methanol (9:1, v/v) mixture. The bands were detected under UV light, scraped off the plate, and metabolism of the radiolabeled substrate was then evaluated by scintillation counting and the substrate conversion determined and compared with the control sample. Data (mean \pm SD) were normalized to the control (DMSO) sample and obtained from at least three independent experiments.

11 β -hsd2 activity in mouse kidney homogenates

The determination of 11 β -hsd2 activity in mouse kidney homogenates was conducted as described earlier (41). Briefly,

for homogenate preparation, kidneys from adult male mice (C57BL6) were snap-frozen and sonicated in homogenization buffer [250 mM sucrose, 10 mM HEPES (pH 7.4); 900 μ l for 100 mg of tissue]. Then, the homogenate was centrifuged (2,000 g, 4°C for 10 min) and the total protein concentration determined. The enzymatic reaction was assessed using 0.075 mg/ml total protein of the kidney homogenate in incubation buffer [300 mM NaCl, 20 mM Tris/HCl, 1 mM EDTA, 10% glycerol (pH 7.7)], different concentrations of oxysterols, 50 nM of corticosterone (containing 50 nCi [1,2,6,7-³H] corticosterone), and 500 μ M NAD⁺ at 37°C for 20 min. Corticosterone and 11-dehydrocorticosterone were separated using TLC. Substrate conversion was determined by scintillation counting. Data (mean \pm SD) were normalized to vehicle control (DMSO) and obtained from at least three independent experiments.

Mineralocorticoid receptor reporter gene assay

HEK-293 cells stably expressing 11 β -HSD2 (AT8 cells) were seeded (100,000 cells per well) in poly-L-lysine-coated 24-well plates and incubated for 24 h. Then, the cells were transiently transfected with the mineralocorticoid receptor (MR) (300 ng/well), a TAT3-TATA luciferase reporter (450 ng/well), and a pCMV-lacZ β -galactosidase transfection control (25 ng/well) using the calcium phosphate precipitation method. At 6 h post-transfection, the cells were washed with DMEM and incubated for another 18 h before replacing the medium with cDMEM. The cells were cultured for another 2 h at 37°C. The medium was then again replaced with fresh cDMEM containing 50 nM cortisol in the presence or absence of different concentrations (78–2,500 nM) of 7k27OHC and 7 β 27OHC, and incubated for 24 h. The cells were lysed with Tropix lysis solution (Applied Biosystems, Foster City, CA) containing 0.5 mM of dithiothreitol and frozen at –80°C for at least 20 min. Luciferase activity was measured by the addition of D-luciferin-firefly substrate solution [0.47 mM D-luciferin, 53 mM ATP, 0.27 mM CoA, 0.13 mM EDTA, 33.3 mM dithiothreitol, 8 mM MgSO₄, 20 mM tricine (pH 7.8)]. β -Galactosidase activity was determined using the Tropix kit. Data (mean \pm SD) were normalized to the control (50 nM cortisol) and obtained from three independent experiments.

ROR γ reporter gene assays

Doxycycline-inducible ROR γ CHO Tet-on cells were transfected with 11 β -HSD1/H6PDH, 11 β -HSD2, or pcDNA3 using the electroporation method according to the manufacturer's protocol (NeonTM transfection system; Invitrogen). Briefly, the cells were resus per well). Three electric pulses of 1,620 V and 10 ms were delivered to the cells using a 100 μ l gold tip. Then, the cells (20,000 cells per well) were seeded in 96-well plates using culture medium without antibiotics and incubated for 16 h. The medium was replaced with medium containing charcoal-dextran stripped FBS for 1.5 h before treating the cells with different concentrations of oxysterols. After 6 h, 1.25 μ M of the inverse agonist SR2211 was added to the treatment for another 2 h. To induce ROR expression, the cells were additionally subjected to 1 μ M doxycycline for a further 16 h. The cells were lysed in 20 μ l Tropix lysis solution supplemented with 0.5 mM dithiothreitol. ROR γ -mediated activation of the luciferase reporter was measured in 10 μ l lysate by adding 100 μ l of D-luciferin-firefly substrate solution. Data (mean \pm SD) were obtained from at least three independent experiments.

Molecular docking calculations

GOLD software (version 5.2, Cambridge Crystallographic Data Centre, Cambridge, UK) was applied to identify accurate docking poses for oxysterols in the binding sites of 11 β -HSDs (42). Interactions found between the ligands and the proteins were further

assessed by the use of LigandScout 3.12 (Inte:Ligand GmbH, Vienna, Austria). This software analyzes the interaction patterns between the protein and the docked ligand, based on the geometric distances, angles, and chemical functionalities (43).

For 11 β -HSD1 docking calculations, the crystal structure with the Protein Data Bank entry 2BEL (<https://www.rcsb.org/structure/2BEL>) was selected for the human protein and for the mouse ortholog the Protein Data Bank entry 1Y5R (<https://www.rcsb.org/structure/1Y5R>). The co-crystallized ligands, carbenoxolone (2BEL) and corticosterone (1Y5R), were extracted from the ligand binding sites in order to be redocked and examined to determine whether GOLD could restore the original binding orientation. The binding site was defined as spherical space (9 Å, respectively 10 Å radius) centered on the hydroxyl group of Tyr183 in 2BEL (X = 3.08; Y = 19.19; Z = 13.65) and 1Y5R (X = 76.88; Y = 49.68; Z = 38.08). The applied settings were validated and showed RMSD values of 0.563 for carbenoxolone and 0.683 for corticosterone.

Two homology models were used for docking calculations for human (44) and murine (45) 11 β -HSD2. The docking settings for the human 11 β -HSD2 binding site were focused on following coordinates X = –20.5; Y = –0.60; Z = 11.38 surrounded by a 12 Å sphere. The residues, Arg212 and Ser152 (Ser219 in full-length protein), were edited as flexible. The settings for the mouse 11 β -hsd2 binding site were centered on the coordinates X = –19.7; Y = 1; Z = 10.5 and defined as spherical space with a 10 Å radius. The amino acid, Trp276, was set flexible.

RESULTS

11 β -HSD1-dependent oxoreduction of 7k27OHC

In order to investigate whether 11 β -HSD1 metabolizes 7k27OHC, HEK-293 cells stably expressing human 11 β -HSD1 and H6PDH were treated with 1 μ M of 7k27OHC in the presence or absence of the specific 11 β -HSD1 inhibitor, T0504. 7k27OHC was stereo-specifically converted to 7 β 27OHC (Fig. 1A, supplemental Fig. S2), with an apparent enzyme velocity (V_{app}) value of 0.52 ± 0.10 nmol·h^{–1}·mg total protein^{–1} compared with a V_{app} of 1.59 ± 0.25 nmol·h^{–1}·mg




Fig. 1. 11 β -HSD1-dependent metabolism of 7k27OHC in intact cells. HEK-293 cells stably expressing human 11 β -HSD1 and H6PDH were treated with 1 μ M of 7k27OHC with or without the 11 β -HSD1 inhibitor T0504 (A) or 1 μ M of 7 β 27OHC or 7 α 27OHC (B) for 60 min. 7k27OHC, 7 β 27OHC, and 7 α 27OHC concentrations were determined using UHPLC-MS/MS. Data represent the mean \pm SD from three independent experiments.

total protein⁻¹ for cortisone (46) as substrate (Table 1). No 7 α 27OHC was generated. Moreover, neither 7 α 27OHC nor 7 β 27OHC was oxidized by 11 β -HSD1 under the conditions applied and no isomerase activity could be detected (Fig. 1B). Enzyme kinetic analysis using microsomal preparations revealed an estimated apparent K_{Mapp} value of 39 ± 12 nM and an apparent $V_{max app}$ value of 4.3 ± 0.2 nmol·h⁻¹·mg total protein⁻¹ for the oxoreduction of 7k27OHC to 7 β 27OHC by 11 β -HSD1 (Table 1). Additionally, mouse 11 β -hsd1 also showed the exclusive conversion of 7k27OHC to 7 β 27OHC without the formation 7 α 27OHC (data not shown).

11 β -HSD2-dependent oxidation of 7 β 27OHC

The role of 11 β -HSD2 in the metabolism of 7-oxygenated 27OHCs was then assessed in HEK-293 cells stably expressing the recombinant human enzyme. Treatment for 30 min with 500 nM of 7 β 27OHC or 7 α 27OHC showed the exclusive oxidation of 7 β 27OHC to 7k27OHC (Fig. 2A) and a lack of 7 α 27OHC metabolism (Fig. 2B, supplemental Fig. S2). Apparent enzyme velocity values were determined as 0.6 ± 0.1 nmol·h⁻¹·mg total protein⁻¹ for 7 β 27OHC and 1.01 ± 0.35 nmol·h⁻¹·mg total protein⁻¹ for cortisone (46) (Table 1). Furthermore, neither an oxoreductase nor an isomerase activity of 11 β -HSD2 could be detected (Fig. 2B). Kinetic analyses of the oxidation reaction of 7 β 27OHC to 7k27OHC revealed a K_{Mapp} value of 56 ± 11 nM and a $V_{max app}$ of 10 ± 0.4 nmol·h⁻¹·mg total protein⁻¹, following a Michaelis-Menten-type response (Table 1).

Metabolism of 7 β OHC by CYP27A1 and 11 β -HSD2

It was recently suggested that 7 β 27OHC formation includes in a first step an oxidation from 7 β OHC to 7kC by 11 β -HSD2, followed by hydroxylation at position 27 by CYP27A1 to 7k27OHC and then reduction of 7k27OHC to 7 β 27OHC by reactive oxygen species (29). Because reductive reactions by reactive oxygen species are highly unlikely, we tested the hypothesis of 27-hydroxylation of 7 β OHC and subsequent oxidation to 7k27OHC in SW-620 colon cancer cells endogenously expressing CYP27A1 and 11 β -HSD2. SW-620 cells were treated with 1 μ M of 7 β OHC in the presence or absence of the 11 β -HSD2 inhibitor, GA, and the formation of 7 β 27OHC (Fig. 3A) and 7k27OHC (Fig. 3B) was evaluated. 7 β 27OHC was generated in a time-dependent manner from 7 β OHC by CYP27A1 and then further oxidized by 11 β -HSD2 to 7k27OHC.

Oxysterol-dependent inhibition of 11 β -HSD enzyme activities

To assess the potential of 7-oxygenated 27OHCs to interfere with the metabolism of glucocorticoids, oxysterol-dependent inhibition of 11 β -HSD enzyme activities were measured in lysates of HEK-293 cells expressing the respective enzymes. 7k27OHC inhibited the 11 β -HSD1-dependent conversion of cortisone to cortisol with an IC_{50} value of 357 ± 38 nM for the human enzyme (Fig. 4A) and of 36 ± 2 nM for the mouse ortholog (Fig. 4B). Only weak inhibition of human 11 β -HSD1 (IC_{50} value ≥ 3 μ M) was detected for 7 β 27OHC, whereas 7 α 27OHC did not inhibit the enzyme activity at concentrations up to 10 μ M (data not shown). However, mouse 11 β -hsd1 enzyme activity was potently inhibited by 7 β 27OHC with an IC_{50} value of 66 ± 11 nM (Fig. 4C) and 1 μ M 7 α 27OHC revealed $\sim 30\%$ rest enzyme activity (data not shown).

11 β -HSD2-dependent conversion of cortisol to cortisone was effectively inhibited by 7 β 27OHC and 7k27OHC with IC_{50} values of 11 ± 2 nM and 15 ± 1 nM, respectively (Fig. 5); however, 7 α 27OHC did not inhibit (not shown). Mouse kidney homogenates, expressing high levels of 11 β -hsd2, were used to determine the interference of oxysterols with the metabolism of corticosterone to 11-dehydrocorticosterone (11-DHC). Neither 7 β 27OHC nor 7 α 27OHC inhibited the 11 β -hsd2 activity, whereas 7k27OHC was a weak inhibitor with an IC_{50} value of 1.65 ± 0.4 μ M (supplemental Fig. S3). Because diminished 11 β -HSD2 activity has been associated with proinflammatory effects and an accelerated formation of atherosclerotic lesions in *Apoe*^{-/-}11 β -hsd2^{-/-} double-knockout mice, due to cortisol-dependent activation of the MR (47), 11 β -HSD2-MR-dependent reporter gene assays were performed. For this purpose, HEK-293 cells stably expressing 11 β -HSD2 were transfected with plasmids for MR and a MR-dependent luciferase reporter gene prior to treatment with cortisol and 7-oxygenated 27OHCs. Following inhibition of 11 β -HSD2 by 7 β 27OHC and 7k27OHC, less cortisol was inactivated to cortisone and thereby an increased (~ 3.5 times) cortisol-dependent MR activation (with EC_{50} values of 354 ± 55 nM for 7 β 27OHC and 331 ± 121 nM for 7k27OHC) compared with the exclusive activation by 50 nM cortisol could be detected (supplemental Fig. S4). Importantly, neither 7 β 27OHC nor 7k27OHC was able to stimulate MR activity by itself (data not shown).

TABLE 1. Kinetic parameters

Enzyme	Reaction	K_{Mapp} (nM)	$V_{max app}$ (nmol·h ⁻¹ ·mg total protein ⁻¹)	$V_{app cell intact}$ (nmol·h ⁻¹ ·mg total protein ⁻¹)
11 β -HSD1	7k27OHC \rightarrow 7 β 27OHC	39 \pm 12	4.3 \pm 0.2	0.52 \pm 0.10 ^a
	Cortisone \rightarrow cortisol	250–500 (19, 34)	—	1.59 \pm 0.25 (46)
11 β -HSD2	7 β 27OHC \rightarrow 7k27OHC	56 \pm 11	10 \pm 0.4	0.6 \pm 0.1 ^b
	Cortisol \rightarrow cortisone	200 (34)	—	1.01 \pm 0.35 (46)

Comparison of the oxoreduction of 7k27OHC and cortisone by 11 β -HSD1 and the oxidation of 7 β 27OHC and cortisol by 11 β -HSD2. Data represent mean \pm SD from three independent experiments.

^aA substrate concentration of 1 μ M was used for the reaction.

^bA substrate concentration of 500 nM was used.




Fig. 2. 11β-HSD2-dependent metabolism of 7β27OHC in intact cells. HEK-293 cells stably expressing human 11β-HSD2 were treated with 500 nM of 7β27OHC with or without 5 μM of the 11β-HSD inhibitor GA (A) or 500 nM of 7k27OHC or 7α27OHC (B) for 30 min. 7k27OHC, 7β27OHC, and 7α27OHC concentrations were determined using UHPLC-MS/MS. Data represent the mean ± SD from three independent experiments.

11β-HSD docking calculations

Molecular docking calculations were implemented to predict the binding orientations of 7k27OHC, 7β27OHC and 7α27OHC in the substrate binding pockets of 11β-HSDs and, thus, providing a potential explanation for the results obtained from the enzyme activity measurements. 7k27OHC, cortisone, and 11-DHC were found to fit within comparable distances to the nicotinamide ring of the cofactor (NADPH) as well as to the catalytic residues Tyr183 and Ser170 of human and mouse 11β-HSD1 (Fig. 6A, C). Moreover, the enzymatic product, 7β27OHC, was orientated toward the important residues of the catalytic triad and the cofactor within similar distances as the substrates to 11β-HSD1 of both species (Fig. 6B, D). Compared with 7β27OHC, 7α27OHC adopted a slightly turned upwards binding orientation in the binding cavity of human 11β-HSD1 and, therefore, showed increased distances to Tyr183, Ser170, and particularly to NADPH (Fig. 6B). However, docking analysis of 7α27OHC to mouse 11β-hsd1 displayed a more favorable alignment with similar distances as the substrates to the binding pocket (Fig. 6D).

Homology models were used for docking analyses due to the absence of 11β-HSD2 crystal structures. 7β27OHC and 7k27OHC were found in close distance to the cofactor NAD⁺ (1.0–1.2 Å) and the catalytic residue Tyr232 (2.8–3.4 Å), whereas 7α27OHC fitted again in a turned upwards position with enlarged distances into the substrate binding site of human 11β-HSD2 (Fig. 7A). A considerable species-specific difference was found between the murine and the human 11β-HSD2 substrate-binding cavity: in close distance to the catalytic residues and the cofactor-binding site, the residue Trp276 limited the size of the substrate-binding pocket and constricted the murine enzyme. In the human model, however, this residue was located outside of the binding cavity. Hence, steric clashes with Trp276 were observed when docking 7β27OHC, 7α27OHC, and 7k27OHC to mouse 11β-hsd2, providing a possible explanation for their weak or inactive interaction potential (Fig. 7B).

Prereceptor regulation of RORγ by 11β-HSDs

A recent study identified 7β27OHC as an endogenously occurring RORγ agonist, whereas 7k27OHC was not able to stimulate full-length RORγ activity in reporter gene assays (31). Thus, the capacity of 11β-HSDs to act as metabolic regulators, providing or inactivating the RORγ ligand, was examined. To obtain these insights, CHO cells stably expressing a Tet-on RORγ vector and a RORE-Luc reporter were additionally transfected with either an hH6PDH-IRES-hHSD11B1 construct (Fig. 8A) or 11β-HSD2 (Fig. 8B) and subjected to treatment with 7k27OHC and 7β27OHC. 7k27OHC was capable of reversing the inhibitory effect of the RORγ antagonist, SR2211, in the same manner as 7β27OHC (white dots, continuous line) upon coexpression of RORγ with 11β-HSD1 (black dots, continuous line) compared with the control (black dots, dashed line). Treating 11β-HSD2 expressing RORγ Tet-on cells with 7β27OHC could not restore RORγ activity and showed the same weak response as 7k27OHC. Additionally, treating the cells with 7α27OHC exhibited the same weak concentration-dependent effect as 7k27OHC when expressing only the control plasmid (data not shown).




Fig. 3. Metabolism of 7βOHC in SW-620 cells endogenously expressing CYP27A1 and 11β-HSD2. SW-620 cells were treated with 1 μM of 7βOHC in the presence or absence of 10 μM of GA for 3.5 h (white bars) or 7 h (gray bars). Qualitative analysis of 7β27OHC (A) and 7k27OHC (B) using the respective areas under the curve (AUC) normalized to the ISTD are illustrated. Data represent the mean ± SD from three independent experiments.




Fig. 4. Inhibition of human (A) and murine (B, C) 11 β -HSD1-dependent oxoreduction of cortisone by 7k27OHC and 7 β 27OHC. HEK-293 cell lysates expressing recombinant human 11 β -HSD1 and H6PDH or murine 11 β -hsd1 were incubated with 200 nM of radiolabeled cortisone, 500 μ M of NADPH, and increasing concentrations of 7k27OHC (A, B) and 7 β 27OHC (C) for 10 min at 37°C. Cortisone to cortisol conversion was determined and compared with the enzyme activity in the control samples (0.1% DMSO). Data represent the mean \pm SD from three independent experiments.

DISCUSSION

The family of oxysterols comprises a large number of compounds; however, their abundance in biological systems is low compared with cholesterol (1). Because several enzymes may act on a given metabolite and the enzymes involved often exhibit promiscuous substrate specificities, the analysis of their biosynthetic pathways is challenging. Moreover, oxysterols possess a high susceptibility for autoxidation, predisposing them to biased study results (1). For example, 7 β 27OHC can be formed either by oxoreduction of 7kC through 11 β -HSD1 to 7 β OHC and then further by hydroxylation to 7 β 27OHC through CYP27A1 or via direct hydroxylation of autoxidation-derived 7 β OHC by CYP27A1. We showed two novel alternative biosynthetic pathways, i.e., the 11 β -HSD1-dependent generation of 7 β 27OHC and the 11 β -HSD2-dependent formation of 7k27OHC. Besides the 11 β -HSD-dependent interconversion of the mono-hydroxylated oxysterols, 7kC and 7 β OHC (19–21, 29), the only reported enzymatic reaction catalyzed by 11 β -HSD2 involving oxysterols was, until now, the oxidation of cholestane-3 β ,5 α ,6 β -triol to the oncometabolite, 6-oxo-cholestane-3 β ,5 α -diol, and the reverse reduction reaction through 11 β -HSD1 (48). Cholestane-3 β ,5 α ,6 β -triol is formed from autoxidation-derived cholesterol-5,6-epoxide upon metabolism by cholesterol-epoxide hydrolase. The current study shows for the first time an involvement of 11 β -HSDs in the interconversion of side chain-oxidized oxysterols, with relevance for ROR γ activation (Fig. 9).

Kinetic analysis revealed remarkably high substrate affinities with estimated K_{Mapp} values in the lower nanomolar range of 11 β -HSD1 and 11 β -HSD2 for 7k27OHC and 7 β 27OHC, respectively. The affinity of 11 β -HSD1 for 7k27OHC obtained in the present study is 6–25 times higher than the affinities previously reported for other endogenously occurring substrates (cortisone and 11-DHC, K_{Mapp} \sim 250–500 nM (19, 34); 7kC, K_{Mapp} \sim 500 nM (19); and 7oxoLCA, K_{Mapp} \sim 1000 nM (49)). Moreover, the substrate affinity of 11 β -HSD2 for 7 β 27OHC is \sim 4 times higher than that of the previously reported cortisol (K_{Mapp} \sim 200 nM) (34).

Apart from their own metabolic conversion by 11 β -HSDs, 7k27OHC and 7 β 27OHC may alter other 11 β -HSD-dependent reactions by competing with these substrates at the substrate-binding pocket and thereby inhibiting the corresponding reaction. In this regard, 7k27OHC moderately inhibited the oxoreduction of cortisone to cortisol by human 11 β -HSD1 (IC_{50} value of 357 nM), therefore less likely being of physiological relevance. In contrast, the inhibitory capacities of 7k27OHC and 7 β 27OHC (IC_{50} values of 15 nM and 11 nM, respectively) to interfere with (human) 11 β -HSD2-dependent oxidation of cortisol belong to the most potent endogenous 11 β -HSD2 inhibitors discovered so far (50). Upon inhibition of 11 β -HSD2, less cortisol is inactivated, resulting in higher cortisol availability and activation of the MR, as shown in transactivation assays. A role for endogenously formed compounds inhibiting 11 β -HSD2 function was raised by the GA-like factor (GALF)




Fig. 5. Inhibition of human 11 β -HSD2-dependent oxidation of cortisol by 7 β 27OHC and 7k27OHC. Lysates of HEK-293 cells expressing recombinant human 11 β -HSD2 were incubated with 50 nM of radiolabeled cortisol, 500 μ M of NAD⁺, and increasing concentrations of 7 β 27OHC (A) and 7k27OHC (B) for 10 min at 37°C. Cortisol to cortisone conversion was determined and compared with the enzyme activity in the control samples (0.1% DMSO). Data represent the mean \pm SD from three independent experiments.




Fig. 6. Predicted binding of cortisone, 11-DHC, 7k27OHC, 7β27OHC, and 7α27OHC to the binding pocket of human (A, B) and murine (C, D) 11β-HSD1. A: Representative binding poses of cortisone (blue), 7k27OHC (green), and 7β27OHC (purple). Important interactions for protein-ligand binding and the cofactor are shown in stick style and corresponding distances in ångstroms are indicated as dashed lines (same color code as docked ligands). B: Binding mode of 7β27OHC and 7α27OHC (salmon pink). C: Representative binding poses of 11-DHC (turquoise) and 7k27OHC. Important interactions for protein-ligand binding and the cofactor are shown in stick style and corresponding distances in ångstroms are indicated as dashed lines (same color code as docked ligands). D: Binding mode of 7k27OHC, 7β27OHC, and 7α27OHC.

hypothesis implicating an involvement in the etiology of not only essential hypertension but also colorectal cancer (50). Such GALFs, derived from peripheral tissues, the adrenal glands, or the gut microbiome could allow cortisol to act as a mineralocorticoid, leading to increased Na⁺ retention and hypertension (50, 51). Furthermore, they may cause elevated intracellular levels of active glucocorticoids, suppressing colorectal tumorigenesis and metastasis through different mechanisms.

An important question addresses the physiological relevance of plasma levels measured for potential GALF substances or oxysterols. Due to the lipophilic nature of oxysterols and the localized expression of oxysterol metabolizing enzymes, their formation and, thus, locally increased concentrations may not be represented by plasma concentrations. Hence, to understand oxysterol-related mechanisms, it is necessary to assess the tissue-specific or even cell-specific localization of biotransformation pathways and the involved substrate and product concentrations. The presented experiments using SW-620 colon carcinoma cells revealed a time-dependent formation of 7k27OHC by CYP27A1 and 11β-HSD2 from 7βOHC, with an accumulation of 7β27OHC upon inhibition of 11β-HSD2. Substantial concentrations of 7kC and 7βOHC may be reached in the gastrointestinal tract and in the liver following the

intake of processed cholesterol-rich food. Both 7kC and 7βOHC were reported to induce inappropriate responses to the intestinal epithelium and thereby may disrupt the intestinal barrier integrity [reviewed in (52, 53)]. Whether these effects are due to 7-oxygenated 27OHC remains to be elucidated. Interestingly, innate lymphoid group 3 (ILC3) cells, which are expressed by the intestinal lymphoid tissue and characterized by the expression of the transcription factor, RORγt, have been described to contribute to the regulation of the intestinal barrier (53, 54). However, a hyperactivation of these RORγt-positive ILC3 cells has been described to contribute to intestinal inflammation (54). Because the nuclear receptors RORγ and RORγt are activated by 7β27OHC, but not or only weakly by 7k27OHC when full-length receptors are considered [(31), present study], 11β-HSDs may have an important role by either providing the active ligand 7β27OHC (cells expressing 11β-HSD1) or protecting the receptors from activation (cells expressing 11β-HSD2). Considering that an overstimulation of ILC3 cells could disturb the intestinal barrier function, a protective role for 11β-HSD2 by inactivating the RORγ ligand 7β27OHC to 7k27OHC is suggested, whereas 11β-HSD1 might aggravate the disturbance. Furthermore, recent evidence proposed that the intestinal lymphoid tissue plays a role in the pathology of inflammatory bowel




Fig. 7. Predicted binding of 7k27OHC, 7 β 27OHC, and 7 α 27OHC to human (A) and murine (B) 11 β -HSD2. Representative binding poses of 7k27OHC (orange), 7 β 27OHC (turquoise), and 7 α 27OHC (gray). Important interactions for protein-ligand binding and the cofactor are shown in stick style and corresponding distances in ångströms are indicated as dashed lines (same color code as docked ligands).

disease (IBD) (55). A subgroup of ILC3s was shown to aggregate in ulcerative colitis and correlate with disease severity [reviewed in (53)]. Moreover, a dysregulation of colonic 11 β -HSD expression has been associated with IBD progression and with increased 11 β -HSD1 and decreased 11 β -HSD2 expression (56–59). This would shift the balance from the inactive ROR γ (t) ligand, 7k27OHC, to the agonist, 7 β 27OHC. However, whether this prereceptor regulation of ROR γ and ROR γ t by 11 β -HSDs is involved in

the pathology of IBD requires further careful and thorough experimental investigation.

It needs to be noted that the mouse is of limited use to address the 11 β -HSD-dependent regulation of ROR γ (t). Our data indicate that while human and murine 11 β -HSD1 both accept 7k27OHC as substrate and 7k27OHC effectively competes with cortisone at the substrate binding pocket, 7 β 27OHC is a high-affinity substrate for human 11 β -HSD2 but seems to be unable to efficiently compete with cortisol for binding to the murine enzyme due to steric hindrance.

Nevertheless, the regulation of ROR γ (t) by 11 β -HSDs should be further investigated in relevant human cell models with endogenous expression of these proteins. However, in vitro assessment of the function of endogenously expressed ROR γ using cell lines is highly complex and suitable cell models have not yet been identified. It is still unclear whether RORs are constitutively active receptors or whether their activities are driven by endogenously occurring (not yet characterized) ligands, including different oxysterols or intermediates of the cholesterol biosynthetic pathway. Compounds of the culture medium and of the cholesterol biosynthetic pathway in a cell endogenously expressing ROR γ might control receptor activity and affect target gene expression. Furthermore, ROR γ can be coexpressed with ROR α and/or the transcriptional repressor, Rev-Erb α , that both can bind to the same RORE response element on promoter regions of target genes (60). The assessment of ROR γ target gene expression can be strongly influenced by ROR α and occasionally also by other nuclear receptors and receptor-associated coregulators that are tissue- and cell-specifically expressed. Therefore, the identification of a suitable cell model endogenously co-expressing ROR γ with correspondingly responsive target genes and either 11 β -HSD1 or 11 β -HSD2 remains challenging. Alternatively, cells might be transfected with a ROR γ -responsive reporter gene to achieve a more reliable readout.

To the best of our knowledge, very few human cell lines endogenously express substantial levels of 11 β -HSD1, usually only following differentiation. A series of our own previous experiments with human and murine macrophages, myocytes, and adipocytes have shown that their




Fig. 8. ROR γ -mediated activation of the luciferase reporter by 7,27OHCs in CHO Tet-on cells transfected with either 11 β -HSD1 (A) or 11 β -HSD2 (B). Reversal of the inhibitory effect of the inverse agonist SR2211 by the addition of 7k27OHC or 7 β 27OHC and its dependence on 11 β -HSD1 or 11 β -HSD2. The reporter activation was illustrated as fold change over the inverse agonist SR2211. Data represent the mean \pm SD from at least three independent experiments.




Fig. 9. Control of ROR γ ligand 7 β 27OHC availability by 11 β -HSDs.

differentiation is severely disturbed after transfection and that 11 β -HSD1 expression is abolished, making these cell lines inapplicable to efficiently study ROR γ regulation.

With respect to 11 β -HSD2, we had used, in a series of preliminary experiments, SW-620 cells that express endogenous ROR γ and also ROR α and observed activation of a previously reported glucose-6-phosphatase luciferase construct (33). The potent ROR γ inverse agonist, GSK2981278, was able to inhibit the reporter gene, although at high concentrations (IC₅₀ of 10 μ M); in contrast, the less potent inverse agonist, SR2211, failed to do so. Because endogenous expression of ROR α and/or Rev-Erb α may interfere with ROR γ activity, we then overexpressed ROR γ in SW-620 cells, which resulted in a more pronounced response and a concentration-dependent decrease of the reporter gene activity by both GSK2981278 and SR2211 (with an IC₅₀ of approximately 0.5 μ M for the latter). Our preliminary data showed that inhibition of 11 β -HSD2 in these cells by GA resulted in a trend toward enhanced ROR γ activity (approximately 10% increase) compared with cells treated with 7 β 27OHC only. This suggests that the conversion of 7 β 27OHC to 7k27OHC by 11 β -HSD2 partially protected ROR γ from 7 β 27OHC but that the experimental setting was not suitable to detect 11 β -HSD2-dependent protection of 7 β 27OHC-mediated ROR γ activation. In addition, knockdown of 11 β -HSD2 by siRNA instead of pharmacological inhibition did not result in a more pronounced effect. The following reasons might explain the failure to detect 11 β -HSD2-dependent regulation of ROR γ in our experimental setting: *a*) autoxidation (thereby inactivation of 7 β 27OHC and insufficient competition with the ROR γ inverse agonist); *b*) further metabolism of the oxysterols during the experiment; *c*) generation of other ROR γ agonists by the cell (for example, formation of 27OHC from cholesterol by CYP27A1); *d*) inappropriate timing (resulting in reporter gene activation before 7 β 27OHC is inactivated by 11 β -HSD2); and *e*) insufficient competition with the inverse agonist (not reaching intracellular concentrations successfully competing with the inverse agonist). Thus, the SW-620 cell line has proven useful to study the

enzymatic conversion of 7 β OHC to 7k27OHC; however, it seems unsuitable to study the 11 β -HSD2-mediated prereceptor regulation of ROR γ .

Future efforts should focus on the identification of suitable cell models, including co-culture models to address possible paracrine effects, to investigate the control of ROR γ activity by 11 β -HSDs. Moreover, the role of 11 β -HSDs on tissue-specific control of 7 β 27OHC levels should be studied in vivo in situations where the activities of these enzymes are impaired.

In conclusion, the present study demonstrated the stereospecific oxoreduction of 7k27OHC to 7 β 27OHC by 11 β -HSD1 and the reverse oxidation reaction from 7 β 27OHC to 7k27OHC catalyzed by human 11 β -HSD2 (Fig. 9). The apparent affinities of 11 β -HSD1 and 11 β -HSD2 for the 7-oxygenated oxysterols were equal or higher than for the glucocorticoids, indicating that they are preferred substrates. Furthermore, by supplying either 7 β 27OHC, the active ligand of ROR γ , or inactivating 7 β 27OHC to 7k27OHC, a novel glucocorticoid-independent prereceptor regulation mechanism by 11 β -HSDs could be shown. Future research to identify suitable cell models to characterize the control of ROR γ activity by 11 β -HSDs and to assess the relevance of 11 β -HSDs in the metabolism of 7-oxygenated oxysterols is warranted. [Fig. 9](#)

The authors thank Dr. Thierry Langer, University of Vienna and Inte:Ligand GmbH, for providing the LigandScout software, Dr. Daniela Schuster, Paracelsus Medical University Salzburg, for providing GOLD software, and Dr. Klaus Seuwen, Novartis Institute for BioMedical Research Basel, for expert input to the project.

REFERENCES

- Schroepfer, G. J., Jr. 2000. Oxysterols: modulators of cholesterol metabolism and other processes. *Physiol. Rev.* **80**: 361–554.
- Guillemot-Legris, O., V. Mutemberezi, and G. G. Muccioli. 2016. Oxysterols in metabolic syndrome: from bystander molecules to bioactive lipids. *Trends Mol. Med.* **22**: 594–614.
- Zarrouk, A., A. Vejux, J. Mackrill, Y. O'Callaghan, M. Hammami, N. O'Brien, and G. Lizard. 2014. Involvement of oxysterols in age-related diseases and ageing processes. *Ageing Res. Rev.* **18**: 148–162.
- Jeitner, T. M., I. Voloshyna, and A. B. Reiss. 2011. Oxysterol derivatives of cholesterol in neurodegenerative disorders. *Curr. Med. Chem.* **18**: 1515–1525.
- Poli, G., F. Biasi, and G. Leonarduzzi. 2013. Oxysterols in the pathogenesis of major chronic diseases. *Redox Biol.* **1**: 125–130.
- Silvente-Poirot, S., F. Dalenc, and M. Poirot. 2018. The effects of cholesterol-derived oncometabolites on nuclear receptor function in cancer. *Cancer Res.* **78**: 4803–4808.
- Vejux, A., and G. Lizard. 2009. Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. *Mol. Aspects Med.* **30**: 153–170.
- Brown, A. J., and W. Jessup. 1999. Oxysterols and atherosclerosis. *Atherosclerosis.* **142**: 1–28.
- Song, J., D. Wang, H. Chen, X. Huang, Y. Zhong, N. Jiang, C. Chen, and M. Xia. 2017. Association of plasma 7-ketocholesterol with cardiovascular outcomes and total mortality in patients with coronary artery disease. *Circ. Res.* **120**: 1622–1631.
- Girão, H., M. C. Mota, J. Ramalho, and P. Pereira. 1998. Cholesterol oxides accumulate in human cataracts. *Exp. Eye Res.* **66**: 645–652.
- Björkhem, I., O. Andersson, U. Diczfalusy, B. Sevastik, R. J. Xiu, C. Duan, and E. Lund. 1994. Atherosclerosis and sterol 27-hydroxylase:

- evidence for a role of this enzyme in elimination of cholesterol from human macrophages. *Proc. Natl. Acad. Sci. USA*. **91**: 8592–8596.
12. Brown, A. J., S. L. Leong, R. T. Dean, and W. Jessup. 1997. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. *J. Lipid Res.* **38**: 1730–1745.
 13. Brown, A. J., G. F. Watts, J. R. Burnett, R. T. Dean, and W. Jessup. 2000. Sterol 27-hydroxylase acts on 7-ketocholesterol in human atherosclerotic lesions and macrophages in culture. *J. Biol. Chem.* **275**: 27627–27633.
 14. Heo, G. Y., I. Bederman, N. Mast, W. L. Liao, I. V. Turko, and I. A. Pikuleva. 2011. Conversion of 7-ketocholesterol to oxysterol metabolites by recombinant CYP27A1 and retinal pigment epithelial cells. *J. Lipid Res.* **52**: 1117–1127.
 15. Fujiyama, J., M. Kuriyama, S. Arima, Y. Shibata, K. Nagata, S. Takenaga, H. Tanaka, and M. Osame. 1991. Atherogenic risk factors in cerebrotendinous xanthomatosis. *Clin. Chim. Acta.* **200**: 1–11.
 16. Javitt, N. B. 1994. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. *FASEB J.* **8**: 1308–1311.
 17. Lyons, M. A., and A. J. Brown. 2001. Metabolism of an oxysterol, 7-ketocholesterol, by sterol 27-hydroxylase in HepG2 cells. *Lipids.* **36**: 701–711.
 18. Lyons, M. A., N. Maeda, and A. J. Brown. 2002. Paradoxical enhancement of hepatic metabolism of 7-ketocholesterol in sterol 27-hydroxylase-deficient mice. *Biochim. Biophys. Acta.* **1581**: 119–126.
 19. Schweizer, R. A., M. Zurcher, Z. Balazs, B. Dick, and A. Odermatt. 2004. Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme. *J. Biol. Chem.* **279**: 18415–18424.
 20. Hult, M., B. Elleby, N. Shafiqat, S. Svensson, A. Rane, H. Jornvall, L. Abrahmsen, and U. Oppermann. 2004. Human and rodent type 1 11beta-hydroxysteroid dehydrogenases are 7beta-hydroxycholesterol dehydrogenases involved in oxysterol metabolism. *Cell. Mol. Life Sci.* **61**: 992–999.
 21. Arampatzis, S., B. Kadereit, D. Schuster, Z. Balazs, R. A. Schweizer, F. J. Frey, T. Langer, and A. Odermatt. 2005. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. *J. Mol. Endocrinol.* **35**: 89–101.
 22. Mitić, T., S. Shave, N. Semjonous, I. McNae, D. F. Cobice, G. G. Lavery, S. P. Webster, P. W. Hadoke, B. R. Walker, and R. Andrew. 2013. 11beta-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo. *Biochem. Pharmacol.* **86**: 146–153.
 23. Odermatt, A., and P. Klusonova. 2015. 11beta-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story. *J. Steroid Biochem. Mol. Biol.* **151**: 85–92.
 24. Mitić, T., R. Andrew, B. R. Walker, and P. W. Hadoke. 2013. 11beta-Hydroxysteroid dehydrogenase type 1 contributes to the regulation of 7-oxysterol levels in the arterial wall through the inter-conversion of 7-ketocholesterol and 7beta-hydroxycholesterol. *Biochimie.* **95**: 548–555.
 25. Hermanowski-Vosatka, A., J. M. Balkovec, K. Cheng, H. Y. Chen, M. Hernandez, G. C. Koo, C. B. Le Grand, Z. Li, J. M. Metzger, S. S. Mundt, et al. 2005. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. *J. Exp. Med.* **202**: 517–527.
 26. Luo, M. J., R. Thieringer, M. S. Springer, S. D. Wright, A. Hermanowski-Vosatka, A. Plump, J. M. Balkovec, K. Cheng, G. J. Ding, D. W. Kawka, et al. 2013. 11beta-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature. *Physiol. Genomics.* **45**: 47–57.
 27. Kipari, T., P. W. Hadoke, J. Iqbal, T. Y. Man, E. Miller, A. E. Coutinho, Z. Zhang, K. M. Sullivan, T. Mitić, D. E. Livingstone, et al. 2013. 11beta-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. *FASEB J.* **27**: 1519–1531.
 28. Savouret, J. F., M. Antenos, M. Quesne, J. Xu, E. Milgrom, and R. F. Casper. 2001. 7-ketocholesterol is an endogenous modulator for the arylhydrocarbon receptor. *J. Biol. Chem.* **276**: 3054–3059.
 29. Raleigh, D. R., N. Sever, P. K. Choksi, M. A. Sigg, K. M. Hines, B. M. Thompson, D. Elnatan, P. Jaishankar, P. Bisignano, F. R. Garcia-Gonzalo, et al. 2018. Cilia-associated oxysterols activate smoothed. *Mol. Cell.* **26**: 346–357. e315.
 30. Myers, B. R., N. Sever, Y. C. Chong, J. Kim, J. D. Belani, S. Rychnovsky, J. F. Bazan, and P. A. Beachy. 2013. Hedgehog pathway modulation by multiple lipid binding sites on the smoothed effector of signal response. *Dev. Cell.* **26**: 346–357.
 31. Sorooosh, P., J. Wu, X. Xue, J. Song, S. W. Sutton, M. Sablad, J. Yu, M. I. Nelen, X. Liu, G. Castro, et al. 2014. Oxysterols are agonist ligands of RORgamma and drive Th17 cell differentiation. *Proc. Natl. Acad. Sci. USA.* **111**: 12163–12168.
 32. Smith, S. H., C. E. Peredo, Y. Takeda, T. Bui, J. Neil, D. Rickard, E. Millerman, J. P. Therrien, E. Nicodeme, J. M. Brusq, et al. 2016. Development of a topical treatment for psoriasis targeting RORgamma: from bench to skin. *PLoS One.* **11**: e0147979.
 33. Slominski, A. T., T. K. Kim, Y. Takeda, Z. Janjetovic, A. A. Brozyna, C. Skobowiat, J. Wang, A. Postlethwaite, W. Li, R. C. Tuckey, et al. 2014. RORalpha and ROR gamma are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. *FASEB J.* **28**: 2775–2789.
 34. Schweizer, R. A., A. G. Atanasov, B. M. Frey, and A. Odermatt. 2003. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. *Mol. Cell. Endocrinol.* **212**: 41–49.
 35. Gumy, C., C. Thurnbichler, E. M. Aubry, Z. Balazs, P. Pfisterer, L. Baumgartner, H. Stuppner, A. Odermatt, and J. M. Rollinger. 2009. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 by plant extracts used as traditional antidiabetic medicines. *Fitoterapia.* **80**: 200–205.
 36. Atanasov, A. G., L. G. Nashev, R. A. Schweizer, C. Frick, and A. Odermatt. 2004. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. *FEBS Lett.* **571**: 129–133.
 37. Liu, W., L. Xu, C. R. Lamberson, L. S. Merckens, R. D. Steiner, E. R. Elias, D. Haas, and N. A. Porter. 2013. Assays of plasma dehydrocholesterol esters and oxysterols from Smith-Lemli-Opitz syndrome patients. *J. Lipid Res.* **54**: 244–253.
 38. Dzyakanchuk, A. A., Z. Balazs, L. G. Nashev, K. E. Amrein, and A. Odermatt. 2009. 11beta-Hydroxysteroid dehydrogenase 1 reductase activity is dependent on a high ratio of NADPH/NADP(+) and is stimulated by extracellular glucose. *Mol. Cell. Endocrinol.* **301**: 137–141.
 39. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. 1985. Measurement of protein using bicinchoninic acid. *Anal. Biochem.* **150**: 76–85.
 40. Kratschmar, D. V., A. Vuorinen, T. Da Cunha, G. Wolber, D. Classen-Houben, O. Doblhoff, D. Schuster, and A. Odermatt. 2011. Characterization of activity and binding mode of glycyrrhetic acid derivatives inhibiting 11beta-hydroxysteroid dehydrogenase type 2. *J. Steroid Biochem. Mol. Biol.* **125**: 129–142.
 41. Beck, K. R., M. Bachler, A. Vuorinen, S. Wagner, M. Akram, U. Griesser, V. Temml, P. Klusonova, H. Yamaguchi, D. Schuster, et al. 2017. Inhibition of 11beta-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole. *Biochem. Pharmacol.* **130**: 93–103.
 42. Jones, G., P. Willett, R. C. Glen, A. R. Leach, and R. Taylor. 1997. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol.* **267**: 727–748.
 43. Wolber, G., and T. Langer. 2005. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. *J. Chem. Inf. Model.* **45**: 160–169.
 44. Yamaguchi, H., T. Akitaya, T. Yu, Y. Kidachi, K. Kamiie, T. Noshita, H. Umetsu, and K. Ryoyama. 2011. Homology modeling and structural analysis of 11beta-hydroxysteroid dehydrogenase type 2. *Eur. J. Med. Chem.* **46**: 1325–1330.
 45. Yamaguchi, H., T. Akitaya, Y. Kidachi, K. Kamiie, T. Noshita, H. Umetsu, and K. Ryoyama. 2011. Mouse 11beta-hydroxysteroid dehydrogenase type 2 for human application: homology modeling, structural analysis and ligand-receptor interaction. *Cancer Inform.* **10**: 287–295.
 46. Beck, K. R., S. Kanagaratnam, D. V. Kratschmar, J. Birk, H. Yamaguchi, A. W. Sailer, K. Seuwen, and A. Odermatt. 2019. Enzymatic interconversion of the oxysterols 7beta,25-dihydroxycholesterol and 7-keto,25-hydroxycholesterol by 11beta-hydroxysteroid dehydrogenase type 1 and 2. *J. Steroid Biochem. Mol. Biol.* **190**: 19–28.
 47. Deuchar, G. A., D. McLean, P. W. F. Hadoke, D. G. Brownstein, D. J. Webb, J. J. Mullins, K. Chapman, J. R. Seckl, and Y. V. Kotelevtsev. 2011. 11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe^{-/-} mice. *Endocrinology.* **152**: 236–246.

48. Voisin, M., P. de Medina, A. Mallinger, F. Dalenc, E. Huc-Claustre, J. Leignadier, N. Serhan, R. Soules, G. Segala, A. Mougel, et al. 2017. Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. *Proc. Natl. Acad. Sci. USA*. **114**: E9346–E9355.
49. Odermatt, A., T. Da Cunha, C. A. Penno, C. Chandsawangbhuwana, C. Reichert, A. Wolf, M. Dong, and M. E. Baker. 2011. Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11beta-hydroxysteroid dehydrogenase 1. *Biochem. J.* **436**: 621–629.
50. Morris, D. J., and J. M. Ridlon. 2017. Glucocorticoids and gut bacteria: “The GALF Hypothesis” in the metagenomic era. *Steroids*. **125**: 1–13.
51. Yang, S., L. Jiang, and M. Z. Zhang. 2013. 11beta-Hydroxysteroid dehydrogenase type ii is a potential target for prevention of colorectal tumorigenesis. *J. Oncobiomarkers*. **1**: 002.
52. Rossin, D., S. Calfapietra, B. Sottero, G. Poli, and F. Biasi. 2017. HNE and cholesterol oxidation products in colorectal inflammation and carcinogenesis. *Free Radic. Biol. Med.* **111**: 186–195.
53. Willinger, T. 2019. Oxysterols in intestinal immunity and inflammation. *J. Intern. Med.* **285**: 367–380.
54. Ohnmacht, C. 2016. Tolerance to the intestinal microbiota mediated by ROR(gamma)(+) cells. *Trends Immunol.* **37**: 477–486.
55. Maloy, K. J., and F. Powrie. 2011. Intestinal homeostasis and its breakdown in inflammatory bowel disease. *Nature*. **474**: 298–306.
56. Ergang, P., K. Vytackova, J. Svec, J. Bryndova, I. Miksik, and J. Pacha. 2011. Upregulation of 11beta-hydroxysteroid dehydrogenase 1 in lymphoid organs during inflammation in the rat. *J. Steroid Biochem. Mol. Biol.* **126**: 19–25.
57. Hussey, M., G. Holleran, S. Smith, M. Sherlock, and D. McNamara. 2017. The role and regulation of the 11beta-hydroxysteroid dehydrogenase enzyme system in patients with inflammatory bowel disease. *Dig. Dis. Sci.* **62**: 3385–3390.
58. Stegk, J. P., B. Ebert, H. J. Martín, and E. Maser. 2009. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. *Mol. Cell. Endocrinol.* **301**: 104–108.
59. Zbáňková, S., J. Bryndová, P. Leden, M. Kment, A. Svec, and J. Pácha. 2007. 11beta-hydroxysteroid dehydrogenase 1 and 2 expression in colon from patients with ulcerative colitis. *J. Gastroenterol. Hepatol.* **22**: 1019–1023.
60. Jetten, A. M. 2009. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. *Nucl. Recept. Signal.* **7**: e003.